Northwest Biotherapeutics (NWBO) Total Current Liabilities (2010 - 2026)

Northwest Biotherapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $83.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities changed 0.1% year-over-year to $83.0 million in Q1 2026; TTM through Mar 2026 was $83.0 million, a 0.1% change from a year earlier, with the FY2025 full-year figure at $91.7 million, up 34.31% from the prior year.
• Total Current Liabilities fell to $83.0 million in Q1 2026 per NWBO's latest filing, from $91.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $130.0 million in Q1 2022 and bottomed at $39.9 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $83.0 million (2026), against an average of $78.3 million.
• Across the five-year window, Total Current Liabilities plunged 72.79% in 2022 and jumped 51.04% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $126.0 million in 2022, then sank by 64.13% to $45.2 million in 2023, then jumped by 51.04% to $68.3 million in 2024, then jumped by 34.31% to $91.7 million in 2025, then retreated by 9.52% to $83.0 million in 2026.
• Per Business Quant, the three latest NWBO Total Current Liabilities figures stand at $83.0 million (Q1 2026), $91.7 million (Q4 2025), and $87.9 million (Q3 2025).